NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Chronic Lymphocytic Leukemia

Interventions: Obinutuzumab

Countries: Argentina

This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina. The study population comprises all patients with chronic lymphocytic leukemia (CLL) that have received the indication for treatment with Obinutuzumab as per routine clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Have received at least one dose of Obinutuzumab as per local label and clinical practice.

Exclusion Criteria:

* Included in clinical trial

Locations (3)

Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina